Cacoub Patrice, Commarmond Cloé, Sadoun David, Desbois Anne Claire
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, UPMC Université Paris 06, UMR 7211, Paris F-75005, France; INSERM, UMR_S 959, Paris F-75013, France; CNRS, FRE3632, Paris F-75005, France; Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-HP, 83 boulevard de l'hôpital, Paris F-75013, France.
Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, UPMC Université Paris 06, UMR 7211, Paris F-75005, France; INSERM, UMR_S 959, Paris F-75013, France; CNRS, FRE3632, Paris F-75005, France; Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-HP, 83 boulevard de l'hôpital, Paris F-75013, France.
Rheum Dis Clin North Am. 2017 Feb;43(1):123-132. doi: 10.1016/j.rdc.2016.09.011. Epub 2016 Oct 22.
Chronic hepatitis C virus (HCV) infection is associated with liver and extrahepatic complications, including B-cell lymphoma, cardiovascular and kidney diseases, glucose metabolism impairment and rheumatic conditions ie, arthralgia, myalgia, cryoglobulinemia vasculitis, sicca syndrome and the production of autoantibodies. The treatment has long been based on interferon alpha (IFN) that was found poorly effective, and contraindicated in many autoimmune/inflammatory disorders because of possible exacerbation of rheumatic disorders. The recent emergence of new oral IFN-free combinations offers an opportunity for HCV infected patients with autoimmune/inflammatory disorders to be cured with a short treatment duration and low risk of side effects.
慢性丙型肝炎病毒（HCV）感染与肝脏及肝外并发症相关，包括B细胞淋巴瘤、心血管疾病和肾脏疾病、糖代谢受损以及风湿性疾病，如关节痛、肌痛、冷球蛋白血症性血管炎、干燥综合征和自身抗体产生。长期以来，治疗一直基于α干扰素（IFN），但发现其效果不佳，并且在许多自身免疫/炎症性疾病中因可能加重风湿性疾病而禁忌使用。最近出现的新型无干扰素口服联合疗法为患有自身免疫/炎症性疾病的HCV感染患者提供了机会，可在短疗程和低副作用风险的情况下治愈疾病。
